Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - American Depositary Shares (NQ:ASND)

227.97 +4.56 (+2.04%)
Streaming Delayed Price Updated: 2:38 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months ↗
Ascendis Pharma announces FDA's extension of the review date for TransCon PTH for adults with hypoparathyroidism to August 14, 2024. TransCon PTH aims to address low calcium levels due to... 
Via Benzinga
News headline image
Masters In Trading - Saturday, May 11 ↗
In this recap of the most recent trading session, I discuss earnings results and the market rally seen throughout the past week. 
Via Talk Markets
News headline image
$100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
ASND Stock Earnings: Ascendis Pharma Reported Results for Q1 2024 ↗
Ascendis Pharma just reported results for the first quarter of 2024. 
Via InvestorPlace
News headline image
Looking Into Ascendis Pharma's Recent Short Interest ↗
 
Via Benzinga
News headline image
$1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
$1000 Invested In This Stock 15 Years Ago Would Be Worth $45,000 Today ↗
 
Via Benzinga
News headline image
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion ↗
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates... 
Via Talk Markets
News headline image
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024 ↗
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the... 
Via Talk Markets
News headline image
These Five Small-Cap Stocks Under The Radar Are Expected To Surge, Says Stock Researcher ↗
Ethan Meyers, the research director at Westfield Capital Management, has a knack for identifying promising investments that have proven fruitful, especially for the Harbor Small Cap Growth Fund, where... 
Via Benzinga
News headline image
How Is The Market Feeling About Ascendis Pharma? ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $70,000 Today ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 7, 2024 ↗
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million. 
Via Benzinga
News headline image
Ascendis Pharma's Earnings: A Preview ↗
 
Via Benzinga
News headline image
$100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Analyst Expectations for Ascendis Pharma's Future ↗
 
Via Benzinga
News headline image
Ascendis Pharma's Growth Hormone Deficiency Candidate Outperforms in Phase 3 Trial ↗
Ascendis Pharma A/S (NASDAQ: ASND) released topline results from Phase 3 foresiGHt trial to compare the efficacy and safety of TransCon hGH (lonapegsomatropin) with placebo and daily hGH (human growth... 
Via Benzinga
News headline image
Recap: Ascendis Pharma Q3 Earnings ↗
 
Via Benzinga
News headline image
Preview: Ascendis Pharma's Earnings ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Ascendis Pharma ↗
 
Via Benzinga
News headline image
Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty ↗
Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in  
Via Benzinga
News headline image
The Latest Analyst Ratings for Ascendis Pharma ↗
 
Via Benzinga
News headline image
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Earnings Preview For Ascendis Pharma ↗
 
Via Benzinga
News headline image
Analyst Expectations for Ascendis Pharma's Future ↗
 
Via Benzinga
News headline image
Earnings Scheduled For September 5, 2023 ↗
Companies Reporting Before The Bell • Procaps Gr (NASDAQ:PROC) is likely to report earnings for its second quarter. 
Via Benzinga
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Ascendis, Alvotech, Shift4, and Waldencast and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Hayward, Ascendis, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.